Best in Biotech 31 Oct 2024
Five T cell engager companies you should know about
Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.
Cancer
- Latest Posts
In Depth 30 Oct 2024
Spatial Transcriptomics: A window into disease
The emerging spatial transcriptomics field is letting researchers map out gene expression in tumor and brain samples. How could this change the way we treat disease?
Best in Biotech 29 Oct 2024
GPCR therapies: Eight promising biotechs hacking the cell signaling pathway
In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines.
Best in Biotech 22 Oct 2024
Eight nanotechnology companies to watch out for
Here are eight nanotechnology companies that are widening the scope in medicine, that you should know about.
In Depth 18 Oct 2024
The AI boom in cancer: Game-changer or just hype?
Is AI just hype or a game-changer? Delve into AI’s contribution to oncology, from diagnostics to drug discovery and personalized treatment.
Best in Biotech 17 Oct 2024
Top six European biotech entrepreneurs to know in 2024 (according to VCs)
We reached out to VCs to nominate prominent European entrepreneurs in the biotech industry who are committed to bringing potentially life-changing treatments to market.
ADVERTISEMENT
ADVERTISEMENT
In Depth 16 Oct 2024
JAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?
Find out more about JAK inhibitors and whether they are a good option for treating inflammatory diseases and cancer.
Podcast 11 Oct 2024
Bispecific ADCs: the next generation of cancer treatments
To talk about bispecific ADCs, and biotechs in Czechia, our conversation this week is with Radek Špíšek, CEO of SOTIO.
How an innovative, data-driven approach is revolutionizing drug discovery for solid tumors
Learn how cancer tissue biobanks and insights into solid tumor heterogeneity are transforming drug discovery and paving the way for innovative treatments.
Podcast 4 Oct 2024
Targeting telomerase to disrupt cancer
Listen to our conversation with Vlad Vitoc, CEO of MAIA, on the pioneering approach of telomere targeting
News and Trends 27 Sep 2024
Aptadir Therapeutics launches to develop new class of RNA inhibitors against cancer and genetic disorders
Italian startup Aptadir Therapeutics has launched with $1.6 million to bring a new class of drugs to the clinic and a technology to be reckoned with.
Podcast 27 Sep 2024
Harnessing the body’s natural targeted protein degradation system to treat diseases
Listen to our conversation with Andrew Hirsch, CEO at C4 Therapeutics, a leader in the targeted protein degradation field.
ADVERTISEMENT
